Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Shenin

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Endocrine, Metabolic & Immune Disorders Drug Targets|April 9, 2008
The use of mycophenolate mofetil for the treatment of systemic sclerosisMax Shenin, Manisha Naik, Chris T Derk
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|April 24, 2010
Primary amyloidosis causing diffuse alveolar hemorrhageMax Shenin, Wen Xiong, Manisha Naik, et al.
BMC Rheumatology|March 20, 2019
A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosisAnnemarie Schorpion, Max Shenin, Robin Neubauer, et al.
Rheumatology (Oxford, England)|October 23, 2009
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosisChris T Derk, Elizabeth Grace, Max Shenin, et al.
The Journal of Rheumatology|January 19, 2010
Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictorsKristin M Ingraham, Marie S O'Brien, Max Shenin, et al.
Rheumatology International|August 12, 2011
Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic casesSteffan W Schulz, Max Shenin, Amy Mehta, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Endocrine, Metabolic & Immune Disorders Drug Targets|April 9, 2008
The use of mycophenolate mofetil for the treatment of systemic sclerosisMax Shenin, Manisha Naik, Chris T Derk
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|April 24, 2010
Primary amyloidosis causing diffuse alveolar hemorrhageMax Shenin, Wen Xiong, Manisha Naik, et al.
BMC Rheumatology|March 20, 2019
A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosisAnnemarie Schorpion, Max Shenin, Robin Neubauer, et al.
Rheumatology (Oxford, England)|October 23, 2009
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosisChris T Derk, Elizabeth Grace, Max Shenin, et al.
The Journal of Rheumatology|January 19, 2010
Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictorsKristin M Ingraham, Marie S O'Brien, Max Shenin, et al.
Rheumatology International|August 12, 2011
Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic casesSteffan W Schulz, Max Shenin, Amy Mehta, et al.
Pageof 1